ASk Questions in GYnecologic Oncology (ASQ-GYO)
Part of paid clinical trials in Detroit, Michigan.
- Sponsor
- Ira Winer
- Study ID
- NCT06339827
- Status
- Recruiting
Conditions
- Cervical Cancer
- Endometrial Cancer
- Gestational Trophoblastic Disease
- Ovarian Cancer
- Vaginal Cancer
- Vulvar Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Administration of the ASk Questions in GYnecologic Oncology (ASQ-GYO) Question Prompt List — BEHAVIORALParticipants are randomized and will receive the ASQ-GYO prompt list within 2 weeks prior to their new patient appointment with the gynecology oncology physician.
Study Details
The goal of this clinical trial is to determine the effectiveness of the ASk Questions in GYnecologic Oncology question prompt list (ASQ-GYO QPL) at improving patient self-efficacy, distress, physician trust, and knowledge compared to usual care during new patient gynecologic oncology visits. Also to determine the acceptability of the ASQ-GYO QPL with new gynecologic oncology patients.
Key Dates
- Start date
- Apr 4, 2024
- Status verified
- Jun 2025
- Primary completion
- May 31, 2027
- Completion
- May 31, 2028
Study Design
- Enrollment
- 70 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- HEALTH_SERVICES_RESEARCH
Arms
- Experimental: Administration of the ASk Questions in GYnecologic Oncology (ASQ-GYO) Question Prompt ListParticipants are provided with a question prompt list
- No Intervention: No administration of the ASk Questions in GYnecologic Oncology (ASQ-GYO) Question Prompt ListParticipants will not be provided with the question prompt list
Primary Outcome Measure
Change in pre- and post-visit self-efficacy scores and compared by trial group [ Time Frame: All participants will complete the PEPPI instrument twice: within 2 weeks of their first visit and again within 1 week after the visit. ]
Central Contacts
- Ira Winer, MD PhD3135769194
- Elizabeth Johns, MD MS313-576-8441
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Barbara Ann Karmanos Cancer Institute | Detroit | Michigan | 48201 | Elizabeth Johns Susan Eggly, PhD (SUB_INVESTIGATOR) Elizabeth Johns, MD MS (SUB_INVESTIGATOR) Larrissa Mattei, MD (SUB_INVESTIGATOR) Anna Gotschlich, PhD (SUB_INVESTIGATOR) Wei Chen, PhD (SUB_INVESTIGATOR) Sam Robinson, PhD (SUB_INVESTIGATOR) Ira Winer, MD PhD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Detroit, MI
By condition
By specialty
By research site
Related Studies
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasPHASE1/PHASE2 · Recruiting · Novartis Pharmaceuticals · Atlanta, Georgia
- BP1001-A in Patients With Advanced or Recurrent Solid TumorsPHASE1 · Recruiting · Bio-Path Holdings, Inc. · Silver Spring, Maryland
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)PHASE1/PHASE2 · Recruiting · PMV Pharmaceuticals, Inc · Irvine, California